Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups
Amadori, S × Suciu, S Willemze, R Mandelli, F Selleslag, D Stauder, R Denzlinger, C Leone, G Fabris, P Muus, P Vignetti, M Hagemeijer-Hausman, Anne Beeldens, F Anak, O De Witte, T #
Ferrata storti foundation
Haematologica vol:89 issue:8 pages:950-956
Background and Objectives. Acute myeloid leukemia (AML) in the elderly is associated with low rates of response to conventional chemotherapy and long-term survival, highlighting the need for innovative treatment strategies. Gemtuzumab ozogamicin (GO) is an immunoconjugate that has shown activity in relapsed AML with a favorable safety profile. The aim of-this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML.